<DOC>
	<DOCNO>NCT02109042</DOCNO>
	<brief_summary>The purpose ( ) study measure much study drug get blood stream long take body get rid give multiple dos , subcutaneously ( SQ ) ( insert needle surface skin lower abdominal area ) , post-menopausal female participant . Information side effect may occur also collect . This study also look special marker call `` biomarkers '' use study osteoporosis and/or effect study drug . There 2 part study . The first part last approximately 6 week second part last approximately 7 week .</brief_summary>
	<brief_title>A Study Blosozumab ( LY2541546 ) Postmenopausal Female Participants</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<criteria>Part A : Overtly healthy postmenopausal ( PMP ) females Part B : PMP woman currently take oral bisphosphonates Have body mass index ( BMI ) screen 19.0 35.0 kilogram per square meter ( kg/m^2 ) Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Have know allergy blosozumab , constituent , relate compound Have abnormality 12lead electrocardiogram ( ECG )</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>